The Trump administration is negotiating an agreement with Eli Lilly and Co. that would guarantee the government’s purchase of nearly 1 million doses of an antibody treatment to combat the CCP Virus. The antibody cocktail is similar to the treatment President Donald Trump received when he contracted the virus.

According to the information provided by Reuters, the agreement made between the administration and the laboratory indicates that Lilly will begin to administer 300,000 doses of the treatment, for which it will be paid $375 million. The payment will be made in the two months following the receipt of the drugs and the money will come from an emergency consignment from the Department of Health. 

After receiving the first batch, the government will have the option of buying 650,000 additional doses for an extra $812.5 million, if it considers it necessary.  

The price per dose is $1,250 according to the contract, but as promised by President Trump, the doses purchased by the United States will be free for American patients. 

In the first week of October, the Trump administration also signed agreements with AstraZeneca and Regeneron Pharmaceuticals for the purchase of similar therapies with antibodies, for a total of 100,000 doses.

President Trump contracted the CCP Virus and after suffering some symptoms he was hospitalized and given a cocktail of drugs that included a set of antibodies produced by the biotechnology companies Regeneron and Eli Lilly.

“It was incredible. I felt good right away. I felt as good three days ago as I do now,” he said in a recorded message posted on his Twitter account on Oct. 7 when he was still isolated and recovering. 

In the video, President Trump promised to do everything possible to get the drug approved quickly for wider use, including expressing a desire to distribute it for free. In 20 days, the president kept his promise, the drug was approved, and Americans will have the drug for free.

According to the health news media Stat, monoclonal antibodies are synthetic versions of those produced naturally by the human immune system to fight viruses.

“The greatest benefit of the treatment was in patients who had not mounted their own effective immune response, suggesting that REGN-COV2 could provide a therapeutic substitute for the natural immune response,” Regeneron President Dr. George Yancopoulos, told the Wall Street Journal.